
NeoGenomics (NEO) Stock Forecast & Price Target
NeoGenomics (NEO) Analyst Ratings
Bulls say
NeoGenomics is well-positioned in the oncology diagnostic testing market due to its wide range of tests, strong network of laboratories, and experienced staff, which provides a competitive advantage in this growing industry. With steady MSD% revenue growth expected in its clinical services business, and a faster growing NGS segment driving revenue growth of 10%+ over the next 3 years, NeoGenomics is poised for further success. Additionally, potential market share gains, test menu expansion, and positive reimbursement changes could further drive growth and increase its market value in the future.
Bears say
NeoGenomics is facing challenges with its NGS business due to competition and reimbursement pressure, and the appointment of a new CFO may bring uncertainty. In addition, while the company reported a modest beat and raise in 1Q including 23% NGS growth, margins remain low and the company may struggle to maintain this level of growth in the long term. Furthermore, the company's current valuation, trading at <2x EV/revenue, does not fully reflect these potential risks and uncertainties.
This aggregate rating is based on analysts' research of NeoGenomics and is not a guaranteed prediction by Public.com or investment advice.
NeoGenomics (NEO) Analyst Forecast & Price Prediction
Start investing in NeoGenomics (NEO)
Order type
Buy in
Order amount
Est. shares
0 shares